Adage Capital Partners
AVTX icon

Adage Capital Partners’s Avalo Therapeutics AVTX Stock Holding History

Adage Capital Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8M Buy
854,000
+304,000
+55% +$4.75M 0.02% 626
2025
Q4 		$9.99M Buy
550,000
+291,231
+113% +$4.92M 0.02% 667
2025
Q3 		$3.29M Buy
+258,769
New +$2.23M 0.01% 773

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Adage Capital Partners's AVTX Position: Q1 2026 in Review

Adage Capital Partners increased its Avalo Therapeutics (AVTX) stake by 55% in Q1 2026, buying an estimated $4.75M and bringing the position to 854,000 shares worth $12.8M. The position accounts for 0.02% of the portfolio, ranked #626.

Adage Capital Partners first reported a position in AVTX in Q3 2025 and has held it in 3 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Adage Capital Partners held 854,000 shares of Avalo Therapeutics worth $12.8M as of Q1 2026.
  • Adage Capital Partners bought 304,000 Avalo Therapeutics shares in Q1 2026, an estimated $4.75M.
  • Avalo Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #626 holding.
  • Adage Capital Partners first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.